HB8324, titled the Great American Healthcare Plan, is a broad health care package that combines tax changes, insurance-market reforms, transparency mandates, and drug-access provisions. The bill would significantly expand health savings accounts (HSAs) by raising contribution limits, broadening what counts as qualified medical expenses, allowing rollovers from FSAs and HRAs, permitting charitable and general public contributions in some circumstances, and extending bankruptcy protections to HSAs. It also allows HSA funds to be used for a wider range of items, including certain health insurance premiums, direct primary care arrangements, healthy food, vitamins, dietary supplements, and sports and fitness expenses, and it permits HSA rollovers to family members in specified cases.
The bill also creates a “Health Marketplace for All” framework that would let qualifying marketplace pools act like employers for purposes of offering group health plans or group health insurance coverage, including drug-only coverage. In addition, it substantially expands price transparency requirements for hospitals, laboratories, imaging providers, ambulatory surgical centers, and health plans. These provisions require public posting of standard charges, negotiated rates, cash prices, and related billing information, and they impose new attestation, audit, and civil penalty requirements for noncompliance. The bill further requires more detailed explanations of benefits and itemized bills for patients, and it gives group health plans greater access to claims, payment, and administrative data from service providers.
A major policy component is the bill’s treatment of prescription drugs and complex therapies. It would require manufacturers of selected Medicare Part B drugs subject to maximum fair price negotiation to pay rebates tied to the difference between ASP+6 payment amounts and maximum-fair-price-based amounts, while preserving beneficiary cost-sharing at the lower level. The bill also creates an expanded-access prescription drug category that would allow certain lower-risk drugs to be dispensed or administered by pharmacists, advanced practice nurses, physician assistants, and other covered professionals under federal protocols, with federal preemption over conflicting state restrictions unless a state affirmatively opts out.
The bill’s impact on state law is mixed but significant. In the transparency and insurance sections, it expressly preserves state price-transparency laws unless they conflict with the federal requirements, and it similarly limits preemption in the HSA and insurance provisions to the extent necessary to carry out the act. By contrast, the expanded-access prescription drug provisions would broadly preempt state licensure or scope-of-practice rules that conflict with the federal framework, subject to a state opt-out. The bill would also amend ERISA, the Internal Revenue Code, the Public Health Service Act, the Social Security Act, the Federal Food, Drug, and Cosmetic Act, and the Bankruptcy Code, affecting employers, health plans, insurers, hospitals, labs, ambulatory surgical centers, third-party administrators, drug manufacturers, patients, and health care professionals.
No committee transcripts or recorded votes were provided, and the bill’s only listed action is referral to multiple committees. As a result, there is no documented legislative debate or vote history in the supplied materials. Based on the text alone, the bill appears designed to appeal to supporters of consumer price transparency, HSA expansion, and broader access to lower-cost care, while also likely drawing scrutiny from hospitals, insurers, pharmacy benefit and administrative service providers, and state regulators because of the compliance burdens, disclosure mandates, and federal preemption provisions.
HB8324 would amend federal tax, health insurance, ERISA, bankruptcy, Medicare, and FDA-related statutes. It would expand HSA eligibility and permissible uses under the Internal Revenue Code, create new federal transparency and disclosure obligations for hospitals, labs, imaging centers, ambulatory surgical centers, health plans, and administrative service providers under the Public Health Service Act and ERISA, and add new rebate and cost-sharing rules for selected Medicare Part B drugs under the Social Security Act. It would also create a new federal pathway for expanded-access prescription drugs under the FDCA and preempt conflicting state laws in that area, while preserving or limiting preemption in other sections as specified.
No committee discussion or vote data were provided, so there is no recorded legislative sentiment in the supplied materials. From the bill text, the measure appears generally pro-consumer and market-oriented, emphasizing lower out-of-pocket costs, more patient pricing information, and broader access to HSAs and certain drugs. At the same time, the bill’s extensive reporting, audit, and penalty provisions suggest it would likely face resistance from affected providers, insurers, and service vendors because of compliance costs and operational changes.
The most likely points of contention are the bill’s broad federal transparency mandates, its strong enforcement and penalty structure, and its preemption of conflicting state rules in the expanded-access drug section. Hospitals, laboratories, ambulatory surgical centers, insurers, and third-party administrators may object to the volume of required disclosures, public posting of negotiated rates, and access-to-data requirements. State officials and professional licensing authorities may also object to the expanded-access drug provisions because they override state scope-of-practice and licensure rules unless a state opts out. Supporters are likely to emphasize patient savings, price clarity, and easier access to care, while critics are likely to focus on administrative burden, privacy concerns, and federal intrusion into state regulation.